La Jolla Pharmaceutical Company (LJPC) 2006年年度报告「NASDAQ」.pdf

1、Table of ContentsUNITED STATES SECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACTOF 1934For the fiscal year ended DECEMBER 31,2006OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGEAC

2、T OF 1934For the transition period from to Commission file number:0-24274LA JOLLA PHARMACEUTICAL COMPANY(Exact name of registrant as specified in its charter)Delaware 33-0361285(State or other jurisdiction(I.R.S.Employerof incorporation or organization)Identification Number)6455 Nancy Ridge Drive,Sa

3、n Diego,CA 92121(Address of principal executive offices,including Zip Code)Registrants telephone number,including area code:(858)452-6600Securities registered pursuant to Section 12(b)of the Act:NoneSecurities registered pursuant to Section 12(g)of the Act:Title of each class:Name of each exchange o

4、n which registered:Common Stock,par value$0.01 per share The Nasdaq Global Market Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes o No Indicate by check mark if the registrant is not required to file reports pursuant to Sectio

5、n 13 or 15(d)of the Act.Yes o No Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),an

6、d(2)has been subject to such filingrequirements for the past 90 days.Yes No o Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein,and will not be contained,to thebest of registrants knowledge,in definitive proxy or information stat